Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|May 23, 2006
RoundTable Healthcare Partners Facilitates Product Acquisitions for Bioniche Pharma
Acquisitions Enhance Bioniche Pharma's Product Portfolio and Leverage New Manufacturing Facility
Advertisement
LAKE FOREST, Ill., May 23 /PRNewswire/ -- RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that its portfolio company Bioniche Pharma Group Limited ("Bioniche Pharma") has acquired three branded pharmaceutical products: Cystistat(TM), RIMSO-50(TM) and Cryoserv(TM). Cystistat was purchased for CND$10 million. Financial terms of the RIMSO-50 and Cryoserv acquisitions were not disclosed. RoundTable and each of Bioniche Pharma's minority shareholders made additional equity investments to fund the acquisitions.
Bioniche Pharma is a leading developer and manufacturer of injectable pharmaceuticals. Cystistat is a patented, frontline therapy for Interstitial Cystitis and other glycosaminoglycan ("GAG") layer deficiencies of the bladder and was purchased from Bioniche Life Sciences, Inc. ("BLSI"), the former parent company of Bioniche Pharma. RIMSO-50 and Cryoserv were purchased from Edwards Lifesciences ("Edwards"). RIMSO-50 is a leading treatment for Interstitial Cystitis in the United States and Canada. Cryoserv is used as a stem cell preservation agent and is sold primarily in the United States with some sales in Europe.
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
3
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
4
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
5